This drug suppresses the expression of inflammation cytokines including TNF-α, IL-1β, and IL-6, which are all considered pro-inflammatory cytokines that are significantly linked to the development and progression of non-alcoholic fatty liver disease (NAFLD), meaning that elevated levels of these cytokines in the blood can indicate an increased risk of NAFLD. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.